Three large randomized trials tested a simple idea: if one blood-pressure drug that blocks the renin-angiotensin system protects diabetic kidneys, two such drugs should protect them better. Each trial found the opposite. Combining an ACE inhibitor with an angiotensin-receptor blocker, or adding the direct renin inhibitor aliskiren to either one, increased rates of acute kidney injury, dangerous potassium spikes, and dialysis in patients with diabetes. European regulators responded by formally contraindicating certain dual combinations in diabetic and renal-impaired patients, yet questions persist about how consistently those warnings are followed in routine clinical practice.
Dual blood-pressure blockade backfired in diabetic kidney disease
The logic behind dual renin-angiotensin system (RAS) blockade was straightforward. ACE inhibitors and ARBs each slow kidney decline in diabetes by lowering pressure inside the glomerulus. Stacking two agents from different points in the same hormonal cascade, the thinking went, should amplify that protection. Three major trials dismantled that hypothesis.
The VA NEPHRON-D trial enrolled veterans with proteinuric diabetic kidney disease and randomized them to lisinopril plus losartan versus losartan alone. In patients assigned to the combination, investigators observed more episodes of acute kidney injury and higher rates of hyperkalemia, and the data safety monitoring board halted the study early because of those harms. The trial’s renal outcomes showed that adding lisinopril to losartan did not slow kidney-function loss and instead increased serious complications, as detailed in the published trial report.
A parallel story played out in the ALTITUDE trial, which tested whether adding aliskiren to standard ACE-inhibitor or ARB therapy would reduce cardiovascular and renal events in high-risk patients with type 2 diabetes. Rather than improving outcomes, aliskiren on top of existing RAS blockade provided no measurable benefit and increased adverse events, including acute renal complications and electrolyte disturbances. These safety concerns led to early termination of the study, as described in the investigators’ published analysis.
The ONTARGET renal-outcomes analysis broadened the picture beyond diabetes-specific cohorts. In a population at high vascular risk, including many patients with diabetes and established end-organ damage, the combination of telmisartan and ramipril increased the rate of dialysis or doubling of serum creatinine compared with either drug used alone. The renal data showed more frequent serious kidney events without offsetting benefit in slowing chronic decline when both agents were prescribed together, according to the detailed renal outcomes report.
Taken together, these trials converged on a clear message. In high-risk patients with diabetes or vascular disease, dual RAS blockade with an ACE inhibitor plus an ARB, or with aliskiren added to either class, did not deliver extra kidney protection. Instead, it raised the likelihood of acute kidney injury, dangerous hyperkalemia, and progression to dialysis. The harms emerged despite careful monitoring, suggesting that risks in routine care-where laboratory follow-up may be less frequent-could be at least as great.
Regulators drew clear lines, but enforcement gaps remain
The trial evidence triggered regulatory action in Europe. The European Medicines Agency completed a referral on RAS-acting agents and concluded that ACE inhibitors and ARBs should not be used together in patients with diabetic nephropathy. The EMA also recommended formal contraindications for aliskiren combined with ACE inhibitors or ARBs in patients who have diabetes or moderate-to-severe renal impairment, citing increased risk of adverse outcomes including changes in renal function, acute renal failure, and hyperkalemia.
The United Kingdom’s MHRA issued its own warnings covering the same territory, flagging hyperkalaemia, hypotension, and impaired renal function as risks of combining medicines from different classes of RAS-blocking agents. These regulatory steps were unambiguous: the drugs in question are among the most commonly prescribed medications worldwide, and the agencies told prescribers to stop pairing them in exactly the patients most likely to receive them. The guidance effectively redrew the boundaries of safe prescribing, restricting combinations that had once been considered a plausible strategy for intensified renal protection.
What the regulatory record does not answer is how thoroughly those warnings filtered into everyday prescribing. Diabetic patients often see multiple specialists, including primary-care physicians, cardiologists, and nephrologists, each of whom may adjust blood-pressure regimens. Electronic prescribing systems vary widely in their ability to flag contraindicated combinations at the point of care, and paper-based practices may rely on manual medication reconciliation. No large-scale audit of primary-care electronic health records has been published showing how often dual RAS prescriptions still reach diabetic patients after the EMA and MHRA actions.
That gap matters because the harm signal from the trials was not subtle. Acute kidney injury and hyperkalemia are life-threatening events, and they occurred at higher rates even in the controlled setting of randomized studies with close monitoring and predefined stopping rules. In routine practice, laboratory checks may be delayed, and patients may present late with symptoms of volume depletion or arrhythmia. If contraindicated combinations remain in circulation despite regulatory warnings, the real-world toll could exceed what the trials captured.
Unanswered questions about long-term kidney decline
The three pivotal trials that drove regulatory action were designed to measure relatively short-term outcomes: acute kidney injury events, hyperkalemia episodes, and composite endpoints combining renal and cardiovascular crises. None of them reported extended follow-up tracking kidney-function trajectories in the years after dual therapy was stopped. That leaves a significant hole in the evidence. If dual RAS blockade accelerates kidney damage through mechanisms beyond acute injury-such as sustained tubular stress, altered autoregulation, or promotion of interstitial fibrosis-the harm could extend well past the treatment period itself.
A testable hypothesis sits at the center of this gap. If primary-care records were analyzed systematically, diabetic patients who received any dual RAS prescription after the contraindications were issued might show steeper declines in estimated glomerular filtration rate over time compared with similar patients treated with a single RAS blocker. Such an analysis would need to account carefully for confounding, because clinicians might reserve dual therapy for patients with more severe hypertension or proteinuria. Nonetheless, longitudinal data from routine practice could help clarify whether even brief exposure to discouraged combinations leaves a lasting imprint on kidney function.
There are also unanswered questions about subgroups. The major trials enrolled high-risk patients with established kidney disease or vascular damage, but many people with diabetes and hypertension have earlier-stage nephropathy or only modest albuminuria. It remains uncertain whether the balance of risk and benefit is equally unfavorable in these lower-risk populations, or whether there might be narrow clinical niches where short-term dual blockade could be justified under intensive monitoring. Regulatory agencies, weighing the overall evidence, have erred on the side of broad contraindications, but clinicians still face decisions at the margins where data are sparse.
For now, the practical message is straightforward. In patients with diabetes or impaired renal function, combining ACE inhibitors with ARBs, or adding aliskiren to either class, has repeatedly failed to improve outcomes and has consistently increased serious kidney-related complications. Regulatory authorities have codified those findings into clear prescribing restrictions, yet the degree to which everyday practice has aligned with that guidance remains uncertain. Closing that gap-through better electronic alerts, medication reviews, and research on real-world prescribing patterns-will be essential to ensure that lessons from VA NEPHRON-D, ALTITUDE, and ONTARGET are fully translated into safer care for people living with diabetic kidney disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
